First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis

Jesper van Breeschoten; Michel W J M Wouters; Doranne L Hilarius; John B Haanen; Christian U Blank; Maureen J B Aarts; Franchette W P J van den Berkmortel; Jan-Willem B de Groot; Geke A P Hospers; Ellen Kapiteijn; Djura Piersma; Roos S van Rijn; Karijn P M Suijkerbuijk; Willeke A M Blokx; Bert-Jan J Ten Tije; Astrid A M van der Veldt; Art Vreugdenhil; Marye J Boers-Sonderen; Alfonsus J M van den Eertwegh

doi:10.1038/s41416-022-01772-z

First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis

Jesper van Breeschoten, Michel W J M Wouters, Doranne L Hilarius, John B Haanen, Christian U Blank, Maureen J B Aarts, Franchette W P J van den Berkmortel, Jan-Willem B de Groot, Geke A P Hospers, Ellen Kapiteijn, Djura Piersma, Roos S van Rijn, Karijn P M Suijkerbuijk, Willeke A M Blokx, Bert-Jan J Ten Tije, Astrid A M van der Veldt, Art Vreugdenhil, Marye J Boers-Sonderen, Alfonsus J M van den Eertwegh

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Abstract

Correction to: British Journal of Cancer https://doi.org/10.1038/s41416-020-01229-1, published online 26 January 2021

The original version of this article unfortunately contained a mistake. During online publication of this article an incorrect notification was included by the Publisher in the Additional Information. The notification incorrectly stated that the licence terms for these articles would switch to a Creative Commons Attribution 4.0 International (CC BY 4.0) after a period of 12 months. This notification has been removed and the articles have been updated.

Original language	English
Article number	1362
Number of pages	1
Journal	British Journal of Cancer
Volume	126
Issue number	9
Early online date	7 Mar 2022
DOIs	https://doi.org/10.1038/s41416-022-01772-z
Publication status	Published - 18 May 2022

Access to Document

10.1038/s41416-022-01772-z

Cite this

van Breeschoten, J., Wouters, M. W. J. M., Hilarius, D. L., Haanen, J. B., Blank, C. U., Aarts, M. J. B., van den Berkmortel, F. W. P. J., de Groot, J.-W. B., Hospers, G. A. P., Kapiteijn, E., Piersma, D., van Rijn, R. S., Suijkerbuijk, K. P. M., Blokx, W. A. M., Tije, B.-J. J. T., Veldt, A. A. M. V. D., Vreugdenhil, A., Boers-Sonderen, M. J., & van den Eertwegh, A. J. M. (2022). First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis. British Journal of Cancer, 126(9), Article 1362. https://doi.org/10.1038/s41416-022-01772-z

@article{247353de7ba942d9b93c259bcd99a713,

title = "First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis",

abstract = "Correction to: British Journal of Cancer https://doi.org/10.1038/s41416-020-01229-1, published online 26 January 2021The original version of this article unfortunately contained a mistake. During online publication of this article an incorrect notification was included by the Publisher in the Additional Information. The notification incorrectly stated that the licence terms for these articles would switch to a Creative Commons Attribution 4.0 International (CC BY 4.0) after a period of 12 months. This notification has been removed and the articles have been updated.",

author = "{van Breeschoten}, Jesper and Wouters, {Michel W J M} and Hilarius, {Doranne L} and Haanen, {John B} and Blank, {Christian U} and Aarts, {Maureen J B} and {van den Berkmortel}, {Franchette W P J} and {de Groot}, {Jan-Willem B} and Hospers, {Geke A P} and Ellen Kapiteijn and Djura Piersma and {van Rijn}, {Roos S} and Suijkerbuijk, {Karijn P M} and Blokx, {Willeke A M} and Tije, {Bert-Jan J Ten} and Veldt, {Astrid A M van der} and Art Vreugdenhil and Boers-Sonderen, {Marye J} and {van den Eertwegh}, {Alfonsus J M}",

note = "Publisher Copyright: {\textcopyright} The Author(s), under exclusive licence to Springer Nature Limited 2022.",

year = "2022",

month = may,

day = "18",

doi = "10.1038/s41416-022-01772-z",

language = "English",

volume = "126",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

number = "9",

}

van Breeschoten, J, Wouters, MWJM, Hilarius, DL, Haanen, JB, Blank, CU, Aarts, MJB, van den Berkmortel, FWPJ, de Groot, J-WB, Hospers, GAP, Kapiteijn, E, Piersma, D, van Rijn, RS, Suijkerbuijk, KPM , Blokx, WAM, Tije, B-JJT, Veldt, AAMVD, Vreugdenhil, A, Boers-Sonderen, MJ & van den Eertwegh, AJM 2022, 'First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis', British Journal of Cancer, vol. 126, no. 9, 1362. https://doi.org/10.1038/s41416-022-01772-z

First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis. / van Breeschoten, Jesper; Wouters, Michel W J M; Hilarius, Doranne L et al.
In: British Journal of Cancer, Vol. 126, No. 9, 1362, 18.05.2022.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients

T2 - a propensity-matched survival analysis

AU - van Breeschoten, Jesper

AU - Wouters, Michel W J M

AU - Hilarius, Doranne L

AU - Haanen, John B

AU - Blank, Christian U

AU - Aarts, Maureen J B

AU - van den Berkmortel, Franchette W P J

AU - de Groot, Jan-Willem B

AU - Hospers, Geke A P

AU - Kapiteijn, Ellen

AU - Piersma, Djura

AU - van Rijn, Roos S

AU - Suijkerbuijk, Karijn P M

AU - Blokx, Willeke A M

AU - Tije, Bert-Jan J Ten

AU - Veldt, Astrid A M van der

AU - Vreugdenhil, Art

AU - Boers-Sonderen, Marye J

AU - van den Eertwegh, Alfonsus J M

PY - 2022/5/18

Y1 - 2022/5/18

N2 - Correction to: British Journal of Cancer https://doi.org/10.1038/s41416-020-01229-1, published online 26 January 2021The original version of this article unfortunately contained a mistake. During online publication of this article an incorrect notification was included by the Publisher in the Additional Information. The notification incorrectly stated that the licence terms for these articles would switch to a Creative Commons Attribution 4.0 International (CC BY 4.0) after a period of 12 months. This notification has been removed and the articles have been updated.

AB - Correction to: British Journal of Cancer https://doi.org/10.1038/s41416-020-01229-1, published online 26 January 2021The original version of this article unfortunately contained a mistake. During online publication of this article an incorrect notification was included by the Publisher in the Additional Information. The notification incorrectly stated that the licence terms for these articles would switch to a Creative Commons Attribution 4.0 International (CC BY 4.0) after a period of 12 months. This notification has been removed and the articles have been updated.

UR - http://www.scopus.com/inward/record.url?scp=85125710952&partnerID=8YFLogxK

U2 - 10.1038/s41416-022-01772-z

DO - 10.1038/s41416-022-01772-z

M3 - Comment/Letter to the editor

C2 - 35256756

SN - 0007-0920

VL - 126

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 9

M1 - 1362

ER -

First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis

Abstract

Access to Document

Other files and links

Fingerprint

Cite this